A clinical-stage biotech company
InteRNA Technologies is a clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging with multiple signal transduction targets simultaneously. With this approach, we address the high unmet medical need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients.
Coordinated regulation of multiple mRNA targets
miRNAs provide a unique simultaneous regulation of multiple messenger RNA (mRNA) targets, and as such block activated cancer signaling pathways, and prevent activation of alternative cancer signaling pathways. These make it then difficult for the cancer to evolve resistance to the therapy and leading to improved long term control of advanced tumors and reduced relapse rates.
